Report

Global cell dissociation market is projected to witness a CAGR of 15.55% during the forecast period 2024-2031, growing from USD 463.03 million in 2023 to USD 1471.53 million in 2031. The market has undergone substantial growth and is expected to further grow manifold in the forecast period.
Cell dissociation, also known as trypsinization, is a process that occurs when adherent cells are separated from the cell culture vessel using a proteolytic enzyme. This process is necessary for the cells to be further consumed. Collagenolytic and proteolytic activities of cell dissociation reagents can increase the viability of the cells and the effectiveness of isolation by releasing the cell tissues and lines from the glass and plastic surfaces of the container.
Market expansion is fueled by ongoing innovation and technological developments in cell dissociation supplies, tools, and processes. The need for cell dissociation is being driven by advancements in technology. These technologies improve efficiency, shorten cycle times, and improve procedure efficacy. The use of sterilization services in medical facilities, labs, and clinical settings is fueled by growing awareness of infection control practices, patient safety, and healthcare-associated infections (HAIs). To prevent the spread of diseases, these processes are essential in providing newer therapeutic models and help researchers produce better healthcare solutions, which is essential.
To meet changing risks and guarantee protection against newly developing infections and resistant strains, cell dissociation providers must constantly innovate and adapt. For instance, in January 2024, Miltenyi Biotec B.V. & Co. KG made the announcement that the company would merge with SynGen Inc. Through this agreement, SynGen Inc.'s cutting-edge cell processing technology and Miltenyi Biotec B.V. & Co. KG's magnetic cell separation know-how were anticipated to be combined, improving both companies' capacities for processing and cell dissociation.
Rising Investments Alongside Rising Mergers and Acquisitions Leading to Market Expansion
The market for cell dissociation is expanding due to rising funding and investments and an increase in mergers and acquisitions. Significant financing for research and development in cell dissociation technologies has come from government efforts, private equity firms, and venture capitalists. Companies can innovate and improve their product with this financial help, which increases their market presence. Furthermore, mergers and acquisitions have greatly aided the expansion of the market. Through these strategic alliances, businesses can pool resources, take use of mutual advantages, and quicken the development and launch of new products. Businesses may meet a wider range of client needs and take advantage of new prospects in the cell dissociation sector by combining technology and skills.
Moreover, heightened investment and consolidation endeavors have nurtured a competitive environment, motivating enterprises to distinguish themselves via innovative technologies and exceptional customer support. In the end, this rivalry benefits all parties involved by fostering innovation and increasing manufacturing and distribution efficiencies. Increasing financing, smart mergers and acquisitions, and other factors are acting together to propel the cell dissociation market's growth and improvement in therapeutic applications and scientific research. For instance, a majority stake of a high-quality cell dissociation reagents provider called Sartorius CellGenix GmbH was acquired by Sartorius AG in October 2023. The strategic alliance between the two can enhance Sartorius AG's product offerings in the cell culture market and can help expand its global footprint.
Growing Prevalence of Infectious Diseases is Fueling Market Growth
The market for cell dissociation is expanding as infectious diseases are becoming more common globally. The need for innovative biomedical research and treatment approaches is rising as infectious illnesses remain a threat to world health. In this context, cell dissociation is essential because it allows researchers to focus on individual cells that are involved in immune responses, infection routes, and disease mechanisms.
To remove and culture cells from different tissues and organs impacted by infectious pathogens, cell dissociation procedures are crucial. Through this approach, scientists can investigate prospective treatments like vaccinations and antiviral medications, analyze the behavior of viruses, and create diagnostic tools. Therefore, it is critical to develop effective and efficient cell dissociation techniques to improve treatment quality and understanding of infectious illnesses. Additionally, the need to address emerging pandemic, newly developing infectious illnesses and antibiotic resistance motivates continued investment in cell dissociation technologies.
Research and development initiatives to improve cell dissociation techniques broaden their uses in infectious disease researches funded by governments, non-profits, and pharmaceutical firms. In summary, the growing incidence of infectious diseases highlights the vital role played by cell dissociation in promoting biomedical research and creating novel approaches to address global health issues, which in turn drives the market for cell dissociation. For instance, the Zika virus epidemics in various countries in 2023 increased the necessity for sophisticated research instruments to comprehend the virus's effect on neural cells, especially in developing and pregnant women and newborns. To isolate and analyze brain stem cells and other pertinent cell types impacted by Zika virus infection, cell dissociation techniques are crucial.
Pharmaceuticals and Biotechnology Companies to Elevate Market Size
The expansion of the cell dissociation market is largely due to the dominance of biotechnology and pharmaceutical firms. These companies are at the forefront of creating novel treatments, vaccinations, and diagnostics which significantly rely on cell dissociation methods for their investigative work. Cell dissociation techniques are used by pharmaceutical corporations to separate particular cell types for drug screening, toxicity assessments, and effectiveness research. These techniques are used by biotechnology companies to cultivate and manipulate cells in controlled conditions to manufacture biologicals, such as recombinant proteins and monoclonal antibodies. The pharmaceutical and biotechnology industries are very competitive and encourage constant innovation in cell dissociation technologies. Businesses make large investments in automation systems, culture media formulations, and dissociation methods to improve the productivity and repeatability of cell-based tests and production processes.
Additionally, strategic alliances and partnerships between biotech startups and industry titans in the pharmaceutical sector drive market expansion. By combining complementary knowledge and resources, these partnerships shorten the time for the development of new products and increase their market share. The prevalence of biotechnology and pharmaceutical industries fuels the need for specialized tools and supplies for cell dissociation operations.
The broad spectrum of suppliers and service providers that are supported by this strong industry ecosystem adds to the overall growth of the cell dissociation market. In conclusion, the importance of pharmaceutical and biotechnology businesses as key players in medicinal development and biomedical research highlights their critical role in propelling growth and development in the cell dissociation market. The emergence of cell-based therapeutics for the treatment of cancer provides a relevant illustration of how the dominance of pharmaceutical and biotechnology corporations drives the cell dissociation market. By 2023, businesses such as Novartis AG and Kite Pharma (a Gilead Sciences, Inc. subsidiary were at the forefront of applying the novel cancer immunotherapy technique known as chimeric antigen receptor (CAR) T-cell therapy.
North America Dominates the Cell Dissociation Market
North America's sophisticated research and healthcare system and strict regulations helped it become the leading region in the global cell dissociation market in 2023. In North America, the market for cell dissociation is anticipated to increase significantly due to factors including the highly developed biopharmaceutical industry, which permits substantial research and development of innovative treatments, and rising firm investment in the development of new therapies. The American Cancer Society released its Cancer Facts & Figures 2023 report, which projected 0.6 million cancer deaths and 1.9 million new cancer cases to be diagnosed in the United States in 2023.
Furthermore, 54.1 million Americans, or 16% of the overall population, were 65 years or older in 2019. By 2040, this number is expected to rise to 21.6% of the overall population. Therefore, it is projected that the country's growing elderly population and the prevalence of chronic diseases will increase the prospects for the development of new biopharmaceuticals, propelling the expansion of the studied market. Furthermore, there is a need for new biopharmaceuticals due to the prevalence of diabetes, cardiovascular diseases (CVDs), and cancer. As a result, the country will have prospects for novel medicines, which will fuel the market expansion.
Future Market Scenario (2024 � 2031F)
Main factors contributing to the anticipated growth of cell dissociation market are the rising awareness about patient safety and infection control, increasing prevalence of pathogens and microorganisms and thus the rising requirement of better therapies. Given that technology is advancing, innovative technology in this field is expected to be introduced. Players in this market are expanding at an un-paralleled rate, introducing cost-effective and efficient technologies. Policies formulated by welfare bodies and government are greatly fueling the market expansion. For instance, a recombinant enzyme for cell dissociation called Gibco TrypLE Express Enzyme was introduced by Thermo Fisher Scientific Inc. in March 2024. The product is intended to offer a more effective and safer substitute for conventional trypsin, leading to better results in cell culture.
Key Players Landscape and Outlook
Several companies are expanding their business by planning and adopting new strategies. They are complying with new strategic initiatives regarding the launches of newly developed cell dissociation technologies to help researchers and market players strengthen their presence in the market. New product launches, agreements based on contracts, acquisitions and mergers, investments and partnerships are a few ways through which they are trying to achieve the same.
For instance, Promega Corporation was acquired by Merck KGaA with the purpose of enhancing its cell dissociation portfolio. Through this acquisition, the product portfolio of Merck KGaA and enzymatic dissociation technologies of Promega Corporation would be combined to improve the dependability and efficiency of cell culture procedures.
To improve its cell dissociation capabilities, Danaher Corporation purchased Global Life Sciences Solutions USA LLC (Cytiva)in February 2024. Cytiva's proficiency in cell processing technologies enhances Danaher Corporation's biopharmaceutical production solutions by supplementing its current portfolio.